These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 25333254

  • 1. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P.
    Oncotarget; 2014 Oct 15; 5(19):8947-58. PubMed ID: 25333254
    [Abstract] [Full Text] [Related]

  • 2. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
    Sison EA, McIntyre E, Magoon D, Brown P.
    Mol Cancer Res; 2013 Sep 15; 11(9):1004-16. PubMed ID: 23754844
    [Abstract] [Full Text] [Related]

  • 3. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M.
    PLoS One; 2013 Sep 15; 8(6):e62785. PubMed ID: 23826077
    [Abstract] [Full Text] [Related]

  • 4. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
    Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S.
    Leuk Lymphoma; 2009 Oct 15; 50(10):1676-86. PubMed ID: 19657955
    [Abstract] [Full Text] [Related]

  • 5. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M.
    Blood; 2009 Jun 11; 113(24):6215-24. PubMed ID: 18955566
    [Abstract] [Full Text] [Related]

  • 6. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    Gravina GL, Mancini A, Muzi P, Ventura L, Biordi L, Ricevuto E, Pompili S, Mattei C, Di Cesare E, Jannini EA, Festuccia C.
    Prostate; 2015 Sep 11; 75(12):1227-46. PubMed ID: 26073897
    [Abstract] [Full Text] [Related]

  • 7. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Ando N, Furuichi Y, Kasai S, Tamai M, Harama D, Kagami K, Abe M, Goi K, Inukai T, Sugita K.
    Leuk Res; 2018 Dec 11; 75():36-44. PubMed ID: 30453100
    [Abstract] [Full Text] [Related]

  • 8. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
    Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P.
    Oncotarget; 2015 Oct 13; 6(31):30902-18. PubMed ID: 26360610
    [Abstract] [Full Text] [Related]

  • 9. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P.
    Br J Haematol; 2013 Mar 13; 160(6):785-97. PubMed ID: 23294096
    [Abstract] [Full Text] [Related]

  • 10. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
    Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA.
    Pediatr Blood Cancer; 2017 Aug 13; 64(8):. PubMed ID: 28409853
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
    Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD.
    Leukemia; 2012 May 13; 26(5):985-90. PubMed ID: 22182920
    [Abstract] [Full Text] [Related]

  • 12. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
    Han AR, Lee JY, Kim HJ, Min WS, Park G, Kim SH.
    Oncol Rep; 2015 Dec 13; 34(6):2880-8. PubMed ID: 26398122
    [Abstract] [Full Text] [Related]

  • 13. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.
    Kato I, Niwa A, Heike T, Fujino H, Saito MK, Umeda K, Hiramatsu H, Ito M, Morita M, Nishinaka Y, Adachi S, Ishikawa F, Nakahata T.
    PLoS One; 2011 Dec 13; 6(11):e27042. PubMed ID: 22069486
    [Abstract] [Full Text] [Related]

  • 14. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro.
    Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ.
    Leukemia; 2003 Jul 13; 17(7):1294-300. PubMed ID: 12835717
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation.
    Ngamsri KC, Jans C, Putri RA, Schindler K, Gamper-Tsigaras J, Eggstein C, Köhler D, Konrad FM.
    Front Immunol; 2020 Jul 13; 11():407. PubMed ID: 32210974
    [Abstract] [Full Text] [Related]

  • 16. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.
    Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, Ratajczak J, Kucia M, Ratajczak MZ.
    Int J Cancer; 2010 Dec 01; 127(11):2554-68. PubMed ID: 20162608
    [Abstract] [Full Text] [Related]

  • 17. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
    Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW.
    Blood; 2012 Sep 27; 120(13):2658-68. PubMed ID: 22889761
    [Abstract] [Full Text] [Related]

  • 18. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
    Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.
    Br J Haematol; 2017 Oct 27; 179(1):36-49. PubMed ID: 28670693
    [Abstract] [Full Text] [Related]

  • 19. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F, Bajetto A, Thellung S, Würth R, Florio T.
    Expert Opin Drug Discov; 2016 Nov 27; 11(11):1093-1109. PubMed ID: 27598329
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
    Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M.
    Mol Cancer Ther; 2006 Dec 27; 5(12):3113-21. PubMed ID: 17172414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.